-
National Multicenter Study on the Prevalence of Carbapenemase-Producing Enterobacteriaceae in the Post-COVID-19 Era in Argentina: The RECAPT-AR Study
-
Infected Fractures and Prosthetic Joints Have Very Similar Microbiology
-
Efflux Pump Inhibitors Enhance Activity of NBTIs Against Gram-Negative Bacteria
-
Vitek Reveal for Antimicrobial Susceptibility Testing from Positive Blood Cultures
Journal Description
Antibiotics
Antibiotics
is an international, peer-reviewed, open access journal on all aspects of antibiotics, published monthly online by MDPI. The Croatian Pharmacological Society (CPS) is affiliated with Antibiotics and its members receive discounts on the article processing charges.
- Open Access— free for readers, with article processing charges (APC) paid by authors or their institutions.
- High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.
- Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics )
- Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.8 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the second half of 2024).
- Recognition of Reviewers: reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.
Impact Factor:
4.3 (2023);
5-Year Impact Factor:
4.6 (2023)
Latest Articles
Pharmacokinetics, Withdrawal Time, and Physiological Effects of Single Oral Administration of Enrofloxacin in Dybowski’s Frog (Rana dybowskii)
Antibiotics 2025, 14(4), 417; https://doi.org/10.3390/antibiotics14040417 (registering DOI) - 19 Apr 2025
Abstract
Background: As a broad-spectrum fluoroquinolone, enrofloxacin (ENR) is commonly employed to manage bacterial infections in aquatic species. Nevertheless, there have been no documented pharmacokinetic and residue studies conducted on Dybowski’s frog (Rana dybowskii). Therefore, the objective of our study was
[...] Read more.
Background: As a broad-spectrum fluoroquinolone, enrofloxacin (ENR) is commonly employed to manage bacterial infections in aquatic species. Nevertheless, there have been no documented pharmacokinetic and residue studies conducted on Dybowski’s frog (Rana dybowskii). Therefore, the objective of our study was to characterize the pharmacokinetics (PK) of ENR and its metabolite ciprofloxacin (CIP) in R. dybowskii, establish withdrawal times, and evaluate the physiological effects associated with ENR administration. Methods: Adult Rana dybowskii (120 individuals; 60 males and 60 females) were sex-separated and acclimated in four tanks. Prior to dosing, three males and three females were randomly selected as untreated controls (without ENR administration). Following the oral gavage of ENR (10 mg/kg), blood, liver, and kidney tissues were collected at 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 24, 36, 48, and 72 h (n = 6) for pharmacokinetic analysis. Muscle and oviduct tissues were additionally sampled at 1, 3, 7, 15, and 30 days post-dose (n = 6) for ENR content determination. Serum/tissue ENR concentrations were measured via Liquid Chromatography–Tandem Mass Spectrometry (LC-MS/MS) and analyzed using a non-compartmental model (WinNonLin 6.1 software) to calculate PK parameters including peak time (Tmax), peak concentration (Cmax), and area under the curve (AUC0−t). In studying the physiology effects of ENR administration, biochemical enzyme activities and gene expressions in the liver and intestine were assessed post-ENR administration. Results: ENR demonstrated rapid absorption and extensive distribution in R. dybowskii. The withdrawal periods were determined to be over 33 days for females and 34 days for males in R. dybowskii. Following ENR administration, there was an increase in immune enzymes (AKP (alkaline phosphatase) and ACP (acid phosphatase)) as well as glycolytic enzymes (HK (hexokinase), PK (pyruvate kinase), PFK (phosphofructokinase)). Antioxidant enzyme levels, specifically SOD (superoxide dismutase) and CAT (catalase), peaked at 1.5 h post-ENR administration but subsequently declined by the 8 h mark. Additionally, following ENR treatment, IGF1, PI3K, and Akt exhibited up-regulation, whereas Keap1 and GYS1 showed down-regulation. Conclusions: The administration of ENR at a dosage of 10 mg/kg significantly enhances the activities of AKP and ACP, promotes glycolysis, and activates the Keap1/Nrf2 and PI3K-Akt signaling pathways in R. dybowskii. These findings establish a foundation for the rational application of ENR and the determination of withdrawal times in frog aquaculture.
Full article
(This article belongs to the Section Antibiotics in Animal Health)
►
Show Figures
Open AccessCase Report
Detection of a Mixed-Strain Infection with Drug- and Multidrug-Resistant Mycobacterium avium Subspecies hominissuis in a Dog with Generalized Lymphadenomegaly
by
Cinzia Marianelli, Angelo Leonori, Romana Stecco and Carlo Giannantoni
Antibiotics 2025, 14(4), 416; https://doi.org/10.3390/antibiotics14040416 (registering DOI) - 19 Apr 2025
Abstract
►▼
Show Figures
Background Members of the Mycobacterium avium complex (MAC) have been documented to cause severe and disseminated infections in dogs, although such cases are sporadically reported. In this study, a comprehensive account of a rare case of generalised lymphadenomegaly caused by a mixed-strain infection
[...] Read more.
Background Members of the Mycobacterium avium complex (MAC) have been documented to cause severe and disseminated infections in dogs, although such cases are sporadically reported. In this study, a comprehensive account of a rare case of generalised lymphadenomegaly caused by a mixed-strain infection with drug- and multidrug-resistant Mycobacterium avium subspecies hominissuis (Mah) in a Maremma sheepdog is presented. Methods Laboratory investigations, as well as the monitoring of the clinical signs displayed by the animal, were conducted throughout the course of a two-year drug therapy (based on rifampicin, azithromycin, and ciprofloxacin) and a two-year post-treatment follow-up period, until the death of the dog. Laboratory examinations included both solid and broth cultures from fine-needle aspiration samples of lymph nodes, molecular typing by 8-locus MIRUVNTR analysis and SNPs typing of five genetic regions (gyrB, rpsA, 3′hsp65, ITS and rpoB), and drug susceptibility testing towards seven antimycobacterial drugs. Results The results indicated the presence of two distinct genotypes of Mah, which exhibited different phenotypic characteristics, such as different drug susceptibility profiles and growth abilities in broth and solid media, suggesting a mixed-strain infection. Resistances to ethambutol alone, to ethambutol and clarithromycin, and to ethambutol, clarithromycin, rifampicin, and doxycycline were detected over the study. Conclusions Although the Mah strains isolated during the course of therapy showed sensitivity to the regiment, the complete eradication of the infection was never achieved. It has been hypothesised that the presence of drug-resistant and multidrug-resistant Mah strains in the animal may have been established at the onset of the infection or soon thereafter. The exposure to therapy has been suggested as a potential factor that could have favoured the growth of resistant strains, thereby rendering the therapy ineffective. The implications that the distinct phenotypic and genotypic profiles of Mah described here may have had for disease dynamics and control are discussed.
Full article

Figure 1
Open AccessArticle
In Vitro Evaluation of the Antibacterial Effect and Influence on the Bacterial Biofilm Formation of Glutamic Acid and Some Structural Analogues
by
Octavia-Laura Oancea, Cristina Nicoleta Ciurea, Anca Delia Mare, Adrian Man, Ruxandra Stefanescu and Aura Rusu
Antibiotics 2025, 14(4), 415; https://doi.org/10.3390/antibiotics14040415 (registering DOI) - 19 Apr 2025
Abstract
Background/Objectives: Glutamic acid (GLA) is an essential amino acid with a key role in human metabolism. A potential involvement in anticancer therapy and possible antibacterial and anti-biofilm effects were also observed. Glutamine (GLN) and monosodium glutamate (MSG) are GLA structural derivatives for
[...] Read more.
Background/Objectives: Glutamic acid (GLA) is an essential amino acid with a key role in human metabolism. A potential involvement in anticancer therapy and possible antibacterial and anti-biofilm effects were also observed. Glutamine (GLN) and monosodium glutamate (MSG) are GLA structural derivatives for which the last two effects were evaluated, with contradictory results. Therefore, this study aimed to assess the antibacterial activity and the influence on the biofilm formation of GLA, GLN, MSG, and glutamic acid diethyl ester (GLADE) on clinically relevant bacteria. Methods: Gram-positive and Gram-negative bacterial reference strains were used to test the antibacterial and anti-biofilm effects of GLA, GLN, MSG, and GLADE. The antibacterial properties were assessed by detecting the minimum inhibitory concentration (MIC) and the minimum bactericidal concentration (MBC). The influence on biofilm formation was assessed by the crystal violet method, reading the optical densities (ODs) by spectrophotometry. Results: GLN did not demonstrate an inhibitory capacity at the maximum tested concentration (2.86 mg/mL); GLA showed inhibitory activity at 1.76 mg/mL and 0.88 mg/mL; MSG inhibited the growth of all bacterial strains at 112 mg/mL; GLADE had the most promising results on all bacterial strains (MICs of 12.75 mg/mL and 25.5 mg/mL). GLADE showed satisfactory MBC values on all bacterial strains (at 51 mg/mL and 25.5 mg/mL). Conclusions: GLA and some structural analogues are attractive options for possible antibacterial activity; optimizing GLADE to increase its antibacterial activity could be a new approach.
Full article
(This article belongs to the Special Issue Methods for Preventing Biofilm Formation and Treat the Infections Caused by Biofilm Formed on Biotics or Abiotic Surfaces)
►▼
Show Figures

Figure 1
Open AccessReview
Bacterial Extracellular Vesicles and Antimicrobial Peptides: A Synergistic Approach to Overcome Antimicrobial Resistance
by
Corina Ciobanasu
Antibiotics 2025, 14(4), 414; https://doi.org/10.3390/antibiotics14040414 (registering DOI) - 19 Apr 2025
Abstract
Antimicrobial resistance is already a major global health threat, contributing to nearly 5 million deaths annually. The rise of multidrug-resistant pathogens has made many infections increasingly difficult to treat. This growing threat has driven the search for alternative therapeutic approaches. Among the most
[...] Read more.
Antimicrobial resistance is already a major global health threat, contributing to nearly 5 million deaths annually. The rise of multidrug-resistant pathogens has made many infections increasingly difficult to treat. This growing threat has driven the search for alternative therapeutic approaches. Among the most promising candidates are bacterial extracellular vesicles (BEVs) and antimicrobial peptides (AMPs), which offer unique mechanisms of action, potential synergistic effects, and the ability to bypass conventional resistance pathways. This review summarizes the current research on synergistic effects of BEVs and AMPs to overcome antimicrobial resistance.
Full article
(This article belongs to the Special Issue Antimicrobial Activity of Bioactive Peptides and Their Derivatives)
►▼
Show Figures

Figure 1
Open AccessArticle
Antimicrobial Susceptibility and Toxin Gene Profiles of Commensal Clostridium perfringens Isolates from Turkeys in Hungarian Poultry Farms (2022–2023)
by
Ádám Kerek, Ábel Szabó, Franciska Barnácz, Bence Csirmaz, László Kovács and Ákos Jerzsele
Antibiotics 2025, 14(4), 413; https://doi.org/10.3390/antibiotics14040413 - 17 Apr 2025
Abstract
Background: The global spread of antimicrobial resistance (AMR) remains one of the greatest challenges of our time, necessitating collaboration among professionals in both the animal and public health sectors. One bacterial species that is developing AMR is Clostridium perfringens. It causes serious
[...] Read more.
Background: The global spread of antimicrobial resistance (AMR) remains one of the greatest challenges of our time, necessitating collaboration among professionals in both the animal and public health sectors. One bacterial species that is developing AMR is Clostridium perfringens. It causes serious bacterial infections and continues to cause significant economic losses in the poultry industry. Methods: This study aimed to evaluate the antimicrobial susceptibility profiles of commensal C. perfringens strains isolated from large-scale turkey flocks in Hungary using minimum inhibitory concentration (MIC) determination. We complemented our research with polymerase chain reaction (PCR) analysis to detect the major and minor toxin genes that are characteristic of the species and to explore the potential associations between gene presence and antimicrobial resistance profiles. Results: A total of 146 commensal isolates were examined. Sensitivity to penicillin was reduced, with only 44.5% of isolates remaining susceptible, whereas 87.7% of isolates were sensitive to amoxicillin. The PCR results revealed that all isolates carried the alpha major toxin gene, 23.9% harbored the beta major toxin gene, 15.8% the beta2 minor toxin gene, 3.4% the NetB minor toxin gene, and 2.7% the epsilon major toxin gene. No statistically significant associations were observed between the presence of toxin genes and the antimicrobial susceptibility profiles of the isolates; the MIC values showed no correlation with the presence of toxin-producing genes. Conclusions: Clostridium perfringens isolates retained susceptibility to beta-lactam antibiotics, which remain the primary choice for treatment. Regular monitoring can aid in establishing temporal trends. Future studies should include larger sample sizes and employ next-generation sequencing to further investigate multidrug-resistant strains.
Full article
(This article belongs to the Special Issue Antibiotics Resistance in Animals and the Environment, 2nd Edition)
►▼
Show Figures

Figure 1
Open AccessArticle
Synergistic Effect of Bacillus and Chitosan: From Flocculation to Enhanced Antimicrobial Activity
by
Selena Dmitrović, Nataša Lukić, Ivana Danilov, Vanja Vlajkov, Jovana Grahovac and Aleksandar Jokić
Antibiotics 2025, 14(4), 412; https://doi.org/10.3390/antibiotics14040412 - 17 Apr 2025
Abstract
Eco-friendly pest management solutions are acknowledged as a crucial element in shaping the future of agriculture through sustainable practices. Achieving the maximum viable cell concentration while being cost-effective is the main goal of the downstream processing for efficient biomass-based microbial biopesticide production. The
[...] Read more.
Eco-friendly pest management solutions are acknowledged as a crucial element in shaping the future of agriculture through sustainable practices. Achieving the maximum viable cell concentration while being cost-effective is the main goal of the downstream processing for efficient biomass-based microbial biopesticide production. The purpose of this study was to determine the effectiveness of chitosan flocculation in recovering bacterial Bacillus sp. BioSol021 biomass from broth cultivated using fruit juice industrial effluent as a medium, with the hypothesis of the synergistic effect of microbial and biopolymer components in phytopathogen suppression. Second-order polynomial models were used to calculate the influence of chitosan concentration and mixing speed on flocculation efficiency, settling velocity, and antibacterial activity against Aspergillus flavus (i.e., the inhibition zone diameter). The response surface approach, followed by desirability function optimization and the genetic algorithm were applied. The optimal values achieved in this study were 97.18%, 0.0369 mm/s, and 74.00 mm for flocculation efficiency, settling velocity, and inhibition zone diameter, respectively. The obtained results suggest that chitosan can be used as a flocculation agent for effective downstream processing, but also has a positive effect on the final product antimicrobial activity.
Full article
(This article belongs to the Special Issue Biotechnological Production of Novel Antimicrobials)
►▼
Show Figures

Figure 1
Open AccessArticle
The Impact of the COVID-19 Pandemic on Pediatric Microbial Resistance Patterns and Abandonment Rates in Western Romania—An Interdisciplinary Study
by
Dan Dumitru Vulcanescu, Iulia Cristina Bagiu, Tiberiu Liviu Dragomir, Virgiliu Bogdan Sorop, Mircea Diaconu, Octavia Harich, Sonia Aniela Tanasescu, Florin Szasz, Luiza Vlaicu, Cosmin Goian and Florin George Horhat
Antibiotics 2025, 14(4), 411; https://doi.org/10.3390/antibiotics14040411 - 16 Apr 2025
Abstract
Background: The COVID-19 pandemic in Romania exacerbated pediatric antimicrobial resistance (AMR). Overuse of broad-spectrum antibiotics may be related to increased multidrug-resistant bacteria. The main aim of this study was to assess pediatric AMR trends and phenotypes, while a secondary objective was to investigate
[...] Read more.
Background: The COVID-19 pandemic in Romania exacerbated pediatric antimicrobial resistance (AMR). Overuse of broad-spectrum antibiotics may be related to increased multidrug-resistant bacteria. The main aim of this study was to assess pediatric AMR trends and phenotypes, while a secondary objective was to investigate the potential links with hospital abandonment. Methods: This retrospective study from the Children’s Emergency Hospital “Louis Țurcanu”, Timișoara, focused on AMR patterns in 2019 pre-pandemic, 2021 pandemic, and 2023 post-pandemic. The following phenotypes were assessed: MRSA, MRCoNS, VRE, ESBL, CRO, MDR, XDR, and PDR. Results: There were 3530 total patients and 6885 total samples. There were 69.92% of the total samples resistant to at least one antimicrobial class, (72.69% in 2019, 67.05% in 2021, 69.16% in 2023). Specifically, resistance towards penicillins remained high across the entire period (57.45–60.93%), while the following classes presented elevated resistance in the pandemic: cephalosporins (42.91%), combination therapies (40.95%), reserve antibiotics (38.89%), and cyclines (13.83%). As for resistance phenotypes, MRSA and MRCoNS peaked during the pandemic (36.08% and 81.43%, respectively) while VRE remained relatively constant. Overall ESBL declined in 2023 to 14.45%, while overall CRO peaked during the pandemic (8.81%). Overall MDR fell during the pandemic (64.47%), while overall XDR peaked in 2019 (9.87%). No PDR cases were observed. Pediatric abandonment was an increasing concern, with regional cases rising from 5.42% (2019) to 9.83% (2023). Compared to the general population, increased antimicrobial resistance in abandoned patients was observed for fluoroquinolones (50.00%), Aminogycolsides (60.00%), reserve antibiotics (70.00%), cephalosporins (60.00%), and urinary antibiotics (60.00%). Resistance to cephalosporins (OR = 5.17, p = 0.0304) and reserve antibiotics (OR = 5.64, p = 0.0049) were key predictors of abandonment risk. Conclusions: The COVID-19 pandemic influenced resistance trends, with notable peaks in MRSA, MRCoNS, and CRO. Post-pandemic patterns suggest continued escalation of resistance. The association between resistant infections and pediatric abandonment highlights the need for robust antimicrobial stewardship and social intervention policies.
Full article
(This article belongs to the Special Issue Antibiotics Use and Stewardship in Hospitals and Outpatient Care Facilities, 2nd Edition)
Open AccessArticle
Antimicrobial Therapies for Early-Onset Group B Streptococcal Sepsis: Insights from an Italian Multicenter Study
by
Valeria Capone, Martina Buttera, Francesca Miselli, Serena Truocchio, Mattia Iaccheri, Cinzia Auriti, Roberta Creti, Lorenza Baroni, Luca Bedetti, Belinda Benenati, Giacomo Biasucci, Jenny Bua, Lidia Decembrino, Luisa Di Luca, Silvia Fanaro, Alessandra Foglianese, Lucia Gambini, Nicola Laforgia, Giuseppe Latorre, Sabrina Loprieno, Gianfranco Maffei, Lucia Marrozzini, Francesca Nanni, Giangiacomo Nicolini, Irene Papa, Barbara Perrone, Giancarlo Piccinini, Maria Rita Pulvirenti, Maria Paola Ronchetti, Enrico Rosati, Daniele Santori, Maria Eleonora Scapillati, Davide Scarponi, Sofia Spinedi, Tzialla Chryssoula, Caterina Vocale, Licia Lugli and Alberto Berardiadd
Show full author list
remove
Hide full author list
Antibiotics 2025, 14(4), 410; https://doi.org/10.3390/antibiotics14040410 - 16 Apr 2025
Abstract
Background: Antimicrobial therapies used for treating group B streptococcus (GBS) early-onset sepsis (EOS) provide insight into clinicians’ adherence to antimicrobial stewardship (AMS) guidelines. Methods: We reviewed antimicrobial therapies given to treat newborns with GBS-EOS. Data were obtained from an Italian surveillance
[...] Read more.
Background: Antimicrobial therapies used for treating group B streptococcus (GBS) early-onset sepsis (EOS) provide insight into clinicians’ adherence to antimicrobial stewardship (AMS) guidelines. Methods: We reviewed antimicrobial therapies given to treat newborns with GBS-EOS. Data were obtained from an Italian surveillance network (including 35 birthing centers) and were prospectively collected from 1 January 2003 to 31 December 2024. Empiric and definitive therapies were classified as adequate and inadequate. Results: There were 967,054 live births and 200 cases of GBS-EOS, of which 43 (21.5%) were preterm and 157 (78.5%) were full-term; 35 (17.5%) out of 200 showed no signs of illness. Fourteen (7.0%) died (one full-term and thirteen preterm newborns under 34 weeks of gestation). Based on the available information, antibiotics were adequate in 106/137 (77.4%) empiric and 48/119 (40.3%) definitive therapies. The duration of antibiotic courses did not differ between severe (median 10 days, IQR 8.0–14.0) and non-severe cases (median: 10 days; IQR: 10.0–12.5; p = 0.68). Antibiotic treatments lasted ≥ 15 days in 34 (20.1%) out of 169 cases with available information. Conclusions: In this large Italian multicenter study, deviations from international recommendations in antimicrobial therapies for GBS-EOS were critical. Our findings underscore the importance of timely antimicrobial de-escalation and the need to avoid excessively prolonged courses of antimicrobials.
Full article
(This article belongs to the Special Issue Neonatal Infections: Epidemiology, Diagnostics and Antibiotic Therapeutics)
►▼
Show Figures

Figure 1
Open AccessArticle
Frequency, Distribution, and Antimicrobial Resistance of Methicillin-Resistant Staphylococci and Mammaliicoccus sciuri Isolated from Dogs and Their Owners in Rio de Janeiro
by
Fernanda Cruz Bonnard, Luciana Guimarães, Izabel Mello Teixeira, Sandryelle Mercês Freire, Alessandra Maia, Patrícia Câmara de Castro Abreu Pinto, Thais Veiga Blanchart and Bruno Penna
Antibiotics 2025, 14(4), 409; https://doi.org/10.3390/antibiotics14040409 - 16 Apr 2025
Abstract
Background: Staphylococcus spp. and Mammaliicoccus sciuri (M. sciuri) are Gram-positive cocci that inhabit mammals’ and birds’ skin and mucous membranes, part of the microbiota. An imbalance in local immunity can increase colonization, resulting in various infections. Inappropriate use of antimicrobials
[...] Read more.
Background: Staphylococcus spp. and Mammaliicoccus sciuri (M. sciuri) are Gram-positive cocci that inhabit mammals’ and birds’ skin and mucous membranes, part of the microbiota. An imbalance in local immunity can increase colonization, resulting in various infections. Inappropriate use of antimicrobials leads to Staphylococci and M. sciuri becoming resistant to conventional treatments. The transmission of methicillin-resistant staphylococci and M. sciuri (MRS and MRMs, respectively) between humans and animals is still underreported in Brazil. Objectives: this study aimed to describe the frequency, distribution, resistance pattern, and evaluation of potential sharing of MRS and MRMs in isolates from asymptomatic dogs and their owners in Rio de Janeiro. Methods: Samples from 50 asymptomatic dogs and 34 from their owners were collected. Isolates were identified by mass spectrometry. The mecA gene was confirmed by conventional PCR. Antimicrobial activity of samples that carried the mecA gene was evaluated by disk diffusion method. Results: In this study, MRS and MRMs were analyzed in 50 dogs and their owners (34) by identifying strains carrying the mecA gene. A total of 185 strains were isolated. The mecA gene was found in 33.5% of the isolates. The most prevalent species carrying the mecA gene was S. epidermidis (33.9%). MRMs showed 14.5%. Fourteen dogs had the same strain carrying the mecA gene as their owners. Of these, 50% exhibited the same antimicrobial resistance pattern, determined by the disk diffusion. The highest percentage of resistance observed in the MRS isolated from dogs and the owners was to Erythromycin (51.3% and 56.5%, respectively). Conclusions: The presence of methicillin-resistant staphylococci is worrisome because there is the potential to transfer these strains between dogs and humans. These strains may act as a reservoir of resistance genes.
Full article
(This article belongs to the Special Issue Antimicrobial Resistance: Epidemiology and Implications for Veterinary Medicine)
►▼
Show Figures

Figure 1
Open AccessArticle
Extended-Spectrum β-Lactamase-Producing Klebsiella pneumoniae in Dogs from Cape Verde and São Tomé and Príncipe: Implications for Public Health
by
Raquel Abreu, Alice Matos, Luís Capela, Rita Jorge, Joana F. Guerreiro, Gonçalo Pereira, Eva Cunha, Lélia Chambel, Luis Tavares, Filip Boyen and Manuela Oliveira
Antibiotics 2025, 14(4), 408; https://doi.org/10.3390/antibiotics14040408 - 16 Apr 2025
Abstract
Antimicrobial resistance is a growing global threat, with surveillance providing essential information to control its spread and support rational treatment strategies. Klebsiella pneumoniae, a member of the Gram-negative Enterobacteriaceae family, frequently develops resistance mechanisms. This study analyzed 195 rectal swabs from companion
[...] Read more.
Antimicrobial resistance is a growing global threat, with surveillance providing essential information to control its spread and support rational treatment strategies. Klebsiella pneumoniae, a member of the Gram-negative Enterobacteriaceae family, frequently develops resistance mechanisms. This study analyzed 195 rectal swabs from companion and stray dogs in Santiago and São Nicolau (Cape Verde) and São Tomé and Príncipe, sampled during a neutering and deworming campaign conducted by Veterinary Without Borders Portugal, to detect extended-spectrum β-lactamase (ESBL)-producing bacteria. Samples were enriched and then cultured on ChromID® ESBL agar, and resulting isolates were identified via MALDI-TOF MS. A total of 35 K. pneumoniae isolates were identified, of which 32 were confirmed as ESBL producers. Antimicrobial susceptibility testing showed 100% resistance to aztreonam, cefotaxime, cefpodoxime, and ceftaroline, and high resistance to cefepime (93.8%), ciprofloxacin (93.8%), and trimethoprim/sulfamethoxazole (90.6%). All isolates were considered multidrug-resistant but remained susceptible to cefoxitin, imipenem, and meropenem. The genes blaCTX-M, blaSHV, and blaTEM were present in 96.9%, 65.6%, and 56.3% of the isolates, respectively. DNA fingerprinting revealed seven clusters, suggesting genetic diversity and strain dissemination across locations. These findings highlight the role of dogs as vectors for antimicrobial resistance dissemination, underscoring the need for continuous surveillance in both veterinary and human medicine.
Full article
(This article belongs to the Special Issue Antimicrobial Resistance: Epidemiology and Implications for Veterinary Medicine)
►▼
Show Figures

Graphical abstract
Open AccessArticle
Molecular Analysis of Tigecycline Resistance in Carbapenem-Resistant Enterobacterales (CRE) in Mthatha and Surrounding Hospitals
by
Luyolo Vumba, Ravesh Singh and Sandeep Vasaikar
Antibiotics 2025, 14(4), 407; https://doi.org/10.3390/antibiotics14040407 - 16 Apr 2025
Abstract
Background: The emergence of carbapenem-resistant Enterobacterales is prevalent and poses a significant threat to health systems worldwide. This study aimed to conduct a molecular analysis of tigecycline resistance in 100 CRE isolates from Mthatha Hospital and surrounding hospitals. Methods: A retrospective study
[...] Read more.
Background: The emergence of carbapenem-resistant Enterobacterales is prevalent and poses a significant threat to health systems worldwide. This study aimed to conduct a molecular analysis of tigecycline resistance in 100 CRE isolates from Mthatha Hospital and surrounding hospitals. Methods: A retrospective study among patients who attended Nelson Mandela Academic Hospital (NMAH) and Mthatha Regional Hospital (MRH), Eastern Cape, South Africa. Enterobacterales isolates were identified using the Vitek2® system (bioMérieux); an E-test was performed on 100 CRE isolates according to the manufacturer’s instructions. PCR assays for rapid detection of tet(X) and its variants, including tet(X1) and tet(X2), and high-level tigecycline resistance genes tet(X3), tet(X4), and tet(X5) were developed. Results: The results show a notably high prevalence of CRE infections in neonatal, male surgical, and maternal and pediatric wards, predominantly driven by Klebsiella species (53.4%), followed by Enterobacter species (20.5%) and then Escherichia coli (6.7%), and 7.2% of CRE isolates were resistant to tigecycline (E-test). In this study, tet(X) genes were not identified as the primary mechanism of tigecycline resistance. The risk factors associated with tigecycline resistance in CRE include age, pre-exposure to antibiotics, prolonged hospitalization, and undergoing invasive procedures, indicated by strong r = 0.9501. Conclusions: CRE gradually evolves, posing a significant threat to patients of all ages; early detection of carbapenemase production in clinical infections, carriage states, or both is essential to prevent hospital-based outbreaks.
Full article
(This article belongs to the Special Issue Antibiotic Use and the Emergence of Antibiotic Resistance in Clinical Settings)
►▼
Show Figures

Figure 1
Open AccessArticle
Intestinal and Extraintestinal Pathotypes of Escherichia coli Are Prevalent in Food Prepared and Marketed on the Streets from the Central Zone of Mexico and Exhibit a Differential Phenotype of Resistance Against Antibiotics
by
Daniela Mora-Coto, Pedro Moreno-Vélez, José Luna-Muñoz, Samadhi Moreno-Campuzano and Miguel Angel Ontiveros-Torres
Antibiotics 2025, 14(4), 406; https://doi.org/10.3390/antibiotics14040406 - 16 Apr 2025
Abstract
►▼
Show Figures
Background/Objectives: Antibiotic resistance is a serious public health problem threatening the treatment of infectious diseases caused by Escherichia coli, the main source of food contamination and responsible for many infectious diseases with high indices of AR profiles. Our objective was to study
[...] Read more.
Background/Objectives: Antibiotic resistance is a serious public health problem threatening the treatment of infectious diseases caused by Escherichia coli, the main source of food contamination and responsible for many infectious diseases with high indices of AR profiles. Our objective was to study the presence of Escherichia coli in foods that are distributed and prepared on the street, characterizing its sensitivity profile and resistance to antibiotic drugs commonly prescribed in this geographical area. Methods: Standard procedures were performed to identify and isolate E. coli colonies from food samples collected during a three-year study. Susceptibility assays were conducted to determine the antibiotic resistance profile, and Colony PCR assays were performed to determine the pathogenic and antibiotic resistance genes. Results: A total of 189 food samples were collected, and 100% of the samples were positive for E. coli, with higher percentages of contamination for vegetables and fruits. ETEC (lt) and UPEC (vat, cnf1, hylA) genes were identified in 100% of the samples and DAEC (afa) in 27%. E. coli exhibited high percentages of resistance against ampicillin and amoxicillin/clavulanic acid (100%) and cephalexin (45%). The most effective antibiotics were tetracycline, TMP-SMX, polymyxin, and quinolones. The AR genes tetA, sul1, catA1, strA, qnrS, and floR were identified among the samples. Conclusions: Food prepared and marketed on the streets seriously threatens human health. Ampicillin and amoxicillin/clavulanic acid should not be used to treat infections caused by the multidrug-resistant ETEC and UPEC identified in this area. To our knowledge, this is the first study that explores the status of AR in this geographical area.
Full article

Figure 1
Open AccessArticle
Impact of the COVID-19 Pandemic on Antibiotic Prescriptions at the University Clinical Dentistry Center of Kosovo
by
Agon Hoti, Ivana Sutej and Arianit Jakupi
Antibiotics 2025, 14(4), 405; https://doi.org/10.3390/antibiotics14040405 - 15 Apr 2025
Abstract
►▼
Show Figures
Background: The COVID-19 pandemic led to significant disruptions in healthcare services worldwide, including dental care, resulting in increased reliance on antibiotics as a substitute for in-person dental interventions. Aim: This study aimed to examine the prescription of different classes of antibiotics at the
[...] Read more.
Background: The COVID-19 pandemic led to significant disruptions in healthcare services worldwide, including dental care, resulting in increased reliance on antibiotics as a substitute for in-person dental interventions. Aim: This study aimed to examine the prescription of different classes of antibiotics at the University Dental Clinical Center of Kosovo during the COVID-19 pandemic and compare it with prescription trends from the pre-pandemic period. Methodology: This study analyzed antibiotic prescription patterns at the University Dental Clinical Center of Kosovo (UCDCK) from 2019 to 2022, focusing on dental patients. Data were collected using a standardized form and a review of electronic health records. Descriptive statistics were used to examine trends, which were compared to data from other countries facing similar healthcare disruptions. The data is organized into quartiles, allowing for a comprehensive understanding of the distribution and trends in antibiotic usage over the four-year period. Results: The study revealed a significant increase in the prescription of broad-spectrum antibiotics, including amoxicillin, clavulanic acid, clindamycin, and metronidazole, during the pandemic period. Data collected from the university dentistry center showed that the highest frequency of antibiotic prescriptions occurred in 2021 (27.6%), while the lowest was in 2022 (22.8%). Metronidazole (39.4%) and amoxicillin with clavulanic acid (38.5%) were the most frequently prescribed antibiotics, together accounting for the majority of prescriptions. Amoxicillin alone represented 18.2%, with other antibiotics prescribed at significantly lower rates. These findings highlight the reliance on these antibiotics for dental treatments and underscore the importance of monitoring prescription trends to optimize usage and minimize resistance risks. Conclusions: The study highlights the impact of the COVID-19 pandemic on dental antibiotic prescription practices in Kosovo, revealing a concerning increase in broad-spectrum antibiotic use. This underscores the need for improved antibiotic stewardship in dental settings, particularly during public health crises, to prevent the exacerbation of antimicrobial resistance. Ensuring continued access to routine dental care and developing robust protocols for antibiotic prescription during emergencies are essential to mitigate the long-term public health impacts of increased antibiotic use.
Full article

Figure 1
Open AccessReview
Novel Antibacterial Approaches and Therapeutic Strategies
by
Gustavo A. Niño-Vega, Jorge A. Ortiz-Ramírez and Everardo López-Romero
Antibiotics 2025, 14(4), 404; https://doi.org/10.3390/antibiotics14040404 - 15 Apr 2025
Abstract
The increase in multidrug-resistant organisms worldwide is a major public health threat driven by antibiotic overuse, horizontal gene transfer (HGT), environmental drivers, and deficient infection control in hospitals. In this article, we discuss these factors and summarize the new drugs and treatment strategies
[...] Read more.
The increase in multidrug-resistant organisms worldwide is a major public health threat driven by antibiotic overuse, horizontal gene transfer (HGT), environmental drivers, and deficient infection control in hospitals. In this article, we discuss these factors and summarize the new drugs and treatment strategies suggested to combat the increasing challenges of multidrug-resistant (MDR) bacteria. New treatments recently developed involve targeting key processes involved in bacterial growth, such as riboswitches and proteolysis, and combination therapies to improve efficacy and minimize adverse effects. It also tackles the challenges of the Gram-negative bacterial outer membrane, stressing that novel strategies are needed to evade permeability barriers, efflux pumps, and resistance mechanisms. Other approaches, including phage therapy, AMPs, and AI in drug discovery, are also discussed as potential alternatives. Finally, this review points out the urgency for continued research and development (R&D), industry–academic partnerships, and financial engines to ensure that MDR microbes do not exceed the value of antibacterial therapies.
Full article
(This article belongs to the Special Issue Evaluation of Emerging Antimicrobials)
►▼
Show Figures

Figure 1
Open AccessArticle
Potential Inhibitory Effect of the Peptide Melittin Purified from Apis mellifera Venom on CTX-M-Type Extended-Spectrum β-Lactamases of Escherichia coli
by
Sheril Ramos-Alcántara, María Alejandra Cornejo Napan, Giovanni Lopez Campana and Jesus Tamariz Ortiz
Antibiotics 2025, 14(4), 403; https://doi.org/10.3390/antibiotics14040403 - 14 Apr 2025
Abstract
Background. Extended-spectrum β-lactamases (ESBLs) hydrolyze nearly all β-lactam antibiotics, affecting one of the most important groups of antimicrobials used in Gram-negative infections. Among them, CTX-M is the most widespread type of ESBL. This study aimed to evaluate the hydrolytic activity of CTX-M-type ESBLs
[...] Read more.
Background. Extended-spectrum β-lactamases (ESBLs) hydrolyze nearly all β-lactam antibiotics, affecting one of the most important groups of antimicrobials used in Gram-negative infections. Among them, CTX-M is the most widespread type of ESBL. This study aimed to evaluate the hydrolytic activity of CTX-M-type ESBLs following exposure to the antimicrobial peptide Melittin. Methods. Melittin was purified from Apis mellifera venom through ultrafiltration and characterized by SDS-PAGE. The minimum inhibitory concentration (MIC) of Melittin against ESBL-producing E. coli was determined by the broth microdilution method. The inhibition of ESBL’s hydrolytic activity following exposure to sub-MIC doses of Melittin was quantified using a kinetic assay based on hydrolyzed nitrocefin. Additionally, the effect of Melittin on the expression of the blaCTX-M gene was evaluated via RT-PCR. Results. The peptide fraction of Apitoxin smaller than 10 kDa exhibited a protein band corresponding to Melittin, devoid of higher molecular weight proteins. The MIC of Melittin ranged from 50 to 80 µg/mL. Exposure to Melittin at sub-MIC doses significantly inhibited ESBL hydrolytic activity, reducing it by up to 67%. However, the transcription of the blaCTX-M gene in the presence of Melittin revealed no significant changes. Conclusions. Melittin is able to inhibit ESBL’s hydrolytic activity but not blaCTX-M transcription possibly indicating an effect at the translational or post-translational level.
Full article
(This article belongs to the Special Issue Bioactive Peptides and Their Antibiotic Activity)
►▼
Show Figures

Figure 1
Open AccessArticle
Repurposing High-Throughput Screening Reveals Unconventional Drugs with Antimicrobial and Antibiofilm Potential Against Methicillin-Resistant Staphylococcus aureus from a Cystic Fibrosis Patient
by
Arianna Pompilio, Veronica Lupetti, Valentina Puca and Giovanni Di Bonaventura
Antibiotics 2025, 14(4), 402; https://doi.org/10.3390/antibiotics14040402 - 14 Apr 2025
Abstract
Background/Objectives: Antibiotic therapy faces challenges from rising acquired and biofilm-related antibiotic resistance rates. High resistance levels to commonly used antibiotics have been observed in methicillin-resistant Staphylococcus aureus (MRSA) strains among cystic fibrosis (CF) patients, indicating an urgent need for new antibacterial agents. This study
[...] Read more.
Background/Objectives: Antibiotic therapy faces challenges from rising acquired and biofilm-related antibiotic resistance rates. High resistance levels to commonly used antibiotics have been observed in methicillin-resistant Staphylococcus aureus (MRSA) strains among cystic fibrosis (CF) patients, indicating an urgent need for new antibacterial agents. This study aimed to identify potential novel therapeutics with antibacterial and antibiofilm activities against an MRSA CF strain by screening, for the first time, the Drug Repurposing Compound Library (MedChem Express). Methods/Results: Among the 3386 compounds, a high-throughput screening-based spectrophotometric approach identified 2439 (72%), 654 (19.3%), and 426 (12.6%) drugs active against planktonic cells, biofilm formation, and preformed biofilm, respectively, although to different extents. The most active hits were 193 (5.7%), against planktonic cells, causing a 100% growth inhibition; 5 (0.14%), with excellent activity against biofilm formation (i.e., reduction ≥ 90%); and 4, showing high activity (i.e., 60% ≤ biofilm reduction < 90%) against preformed biofilms. The potential hits belonged to several primary research areas, with “cancer” being the most prevalent. After performing a literature review to identify other, already published biological properties that could be relevant to the CF lung environment (i.e., activity against other CF pathogens, and anti-inflammatory and anti-virulence potential), the most interesting hits were the following: 5-(N,N-Hexamethylene)-amiloride (diuretic), Toremifene (anticancer), Zafirlukast (antiasthmatic), Fenretide (anticancer), and Montelukast (antiasthmatic) against planktonic S. aureus cells; Hemin against biofilm formation; and Heparin, Clemastine (antihistaminic), and Bromfenac (nonsteroidal anti-inflammatory) against established biofilms. Conclusions: These findings warrant further in vitro and in vivo studies to confirm the potential of repurposing these compounds for managing lung infections caused by S. aureus in CF patients.
Full article
(This article belongs to the Special Issue Strategies to Counteract Mono- and Polymicrobial Biofilm-Related Infections)
►▼
Show Figures

Figure 1
Open AccessArticle
Intravenous Fosfomycin for Difficult-to-Treat Infections: A Real-Life Multicentric Study in Italy
by
Verena Zerbato, Gianfranco Sanson, Lisa Fusaro, Valentina Gerussi, Sara Sincovich, Fabiana Dellai, Giovanni Del Fabro, Nicholas Geremia, Cristina Maurel, Donatella Giacomazzi, Chiara Biasinutto, Filippo Giorgio Di Girolamo, Gianfranco Scrivo, Venera Costantino, Manuela Di Santolo, Marina Busetti, Lory Saveria Crocè, Simone Giuliano, Massimo Crapis, George Zhanel, Carlo Tascini, Roberto Luzzati and Stefano Di Bellaadd
Show full author list
remove
Hide full author list
Antibiotics 2025, 14(4), 401; https://doi.org/10.3390/antibiotics14040401 - 14 Apr 2025
Abstract
Background: Fosfomycin, an old antibiotic attracting renewed interest, offers a broad spectrum of activity and unique synergy with other agents. While widely used in severe infections, real-world data on intravenous fosfomycin remain limited. Objectives: This study aimed to describe the clinical and microbiological
[...] Read more.
Background: Fosfomycin, an old antibiotic attracting renewed interest, offers a broad spectrum of activity and unique synergy with other agents. While widely used in severe infections, real-world data on intravenous fosfomycin remain limited. Objectives: This study aimed to describe the clinical and microbiological characteristics of patients treated with intravenous fosfomycin and to analyze its administration modalities in a real-world setting. Methods: A multicenter retrospective cohort study was conducted across five Italian hospitals. Adult patients receiving intravenous fosfomycin between January 2020 and December 2023 were included. Results: We enrolled 393 patients. The median age was 69 years, with most patients (45%) admitted to Critical Care Units. Pneumonia (34%), bloodstream infections (22%), and urinary tract infections (21%) were the most common indications. Gram-negative bacteria, particularly E. coli and P. aeruginosa, were the predominant pathogens. Fosfomycin was used as empirical therapy in 55% of cases and was combined with other agents in almost all cases (99%). The most frequent partners were piperacillin/tazobactam (21%) and new beta-lactam/beta-lactamase inhibitor combinations (18%). The median treatment duration was seven days, with most subjects (65%) receiving a fosfomycin dosage regimen of 16 g/day. Minimum inhibitory concentrations (MICs) values for fosfomycin were available for 61 isolates (15%), with 78.7% (48/61) showing MIC ≤ 32 mg/L. C. difficile infection occurred in only 2% of patients. Mortality rates at 30, 60, and 90 days were 21.6%, 26.7%, and 29.3%, respectively. Conclusions: This study provides valuable insights into the real-world use of intravenous fosfomycin.
Full article
(This article belongs to the Section Antibiotic Therapy in Infectious Diseases)
►▼
Show Figures

Figure 1
Open AccessArticle
Evaluating Vancomycin Monotherapy and Dual Therapy with Nifuroxazide for Medium–Severe Clostridioides Difficile Infection
by
Jasna Rahimić, Ervin Alibegović, Lana Lekić, Marijana Marković Boras, Amina Džidić-Krivić, Esma Karahmet Farhat and Emina Karahmet Sher
Antibiotics 2025, 14(4), 400; https://doi.org/10.3390/antibiotics14040400 - 14 Apr 2025
Abstract
Background: All currently used therapeutic protocols and drugs for Clostridioides difficile infection (CDI) treatment do not have a satisfying success and usually cost a lot. Objectives: To compare the efficacy of vancomycin monotherapy vs modified dual therapy with vancomycin + nifuroxazide as a
[...] Read more.
Background: All currently used therapeutic protocols and drugs for Clostridioides difficile infection (CDI) treatment do not have a satisfying success and usually cost a lot. Objectives: To compare the efficacy of vancomycin monotherapy vs modified dual therapy with vancomycin + nifuroxazide as a therapeutic protocol for a medium–severe form of CDI. In addition, the effects of a modified therapeutic protocol with standard monotherapy on the number of stools and stool consistency in a medium–severe CDI will be compared. Materials and Methods: A prospective, randomized, controlled clinical trial that included 60 patients divided into two groups was conducted. One group of patients was treated with vancomycin monotherapy. The other group was treated with the modified therapeutic protocol (vancomycin + nifuroxazide). Results: The modified therapy with vancomycin + nifuroxazide demonstrated enhanced pharmacological efficacy in the management of CDI compared to the standard vancomycin monotherapy. Patients treated with dual therapy reported a significantly lower number of stools in first, second and third control; first control (4.47 ± 2.20 compared to 5.70 ± 1.91 in vancomycin group (p = 0.024)), second control (2.37 ± 0.85 compared to 3.13 ± 0.90 in vancomycin group (p = 0.001)), and third control (1.53 ± 0.51 compared to 1.80 ± 0.61 in vancomycin group (p = 0.035)). Also, the first and third controls noted significant improvements in stool consistency, measured as a decrease in the number of completely watery stools (p = 0.011 and p < 0.001, respectively). Conclusions: Nifuroxazide and vancomycin have demonstrated accelerated improvement in patient status and hold promise as a novel dual therapeutic regimen for managing patients diagnosed with a medium–severe form of CDI.
Full article
(This article belongs to the Section Antibiotics Use and Antimicrobial Stewardship)
►▼
Show Figures

Figure 1
Open AccessArticle
Analysis of ESAC-Net/EARS-Net Data from 29 EEA Countries for Spatiotemporal Associations Between Antimicrobial Use and Resistance—Implications for Antimicrobial Stewardship?
by
James C. McSorley
Antibiotics 2025, 14(4), 399; https://doi.org/10.3390/antibiotics14040399 - 13 Apr 2025
Abstract
Background/Objectives: Antimicrobial resistance is one of the foremost global health concerns of today, and it could offset much of the progress accrued in healthcare over the last century. Excessive antibiotic use accelerates this problem, but it is recognised that specific agents differ in
[...] Read more.
Background/Objectives: Antimicrobial resistance is one of the foremost global health concerns of today, and it could offset much of the progress accrued in healthcare over the last century. Excessive antibiotic use accelerates this problem, but it is recognised that specific agents differ in their capacity to promote resistance, a concept recently promoted by the World Health Organisation in the form of its Access, Watch, Reserve (AWaRe) schema. Which, if any, agents should be construed as having a high proclivity for selection of resistance has been contested. The European Antimicrobial Resistance Surveillance Network (EARS-NET) and European Surveillance of Antimicrobial Consumption Network (ESAC-NET) curate population level data over time and throughout the European Economic Area (EEA). EARS-NET monitors resistance to antimicrobials amongst invasive isolates of sentinel pathogens whereas ESAC-NET tracks usage of systemic antimicrobials. Together, data from these networks were interrogated to delineate correlations between antimicrobial consumption and resistance. Methods: Using univariate and multivariate regression analyses, spatiotemporal associations between the use of specific antimicrobial classes and 14 key resistance phenotypes in five sentinel pathogens were assessed methodically for 29 EEA countries. Results: Use of second and third generation cephalosporins, extended spectrum penicillin/β-lactamase inhibitor combinations, carbapenems, fluoroquinolones, nitroimidazoles and macrolides strongly correlated with key resistance phenotypes, as did overall antimicrobial consumption. Conclusions: The data obtained mostly support the WHO AWaRe schema with critical caveats. They have the potential to inform antimicrobial stewardship initiatives in the EEA, highlighting obstacles and shortcomings which may be modified in future to minimise positive selection for problematic resistance.
Full article
(This article belongs to the Section Antibiotics Use and Antimicrobial Stewardship)
►▼
Show Figures

Figure 1
Open AccessArticle
Prevalence, Antimicrobial Resistance Patterns, and Emerging Carbapenemase-Producing Enterococcus Species from Different Sources in Lagos, Nigeria
by
Wasiu Olawale Salami, Samuel Oluwasegun Ajoseh, Aminat Olajumoke Lawal-Sanni, Ashraf A. Abd El Tawab, Heinrich Neubauer, Gamal Wareth and Kabiru Olusegun Akinyemi
Antibiotics 2025, 14(4), 398; https://doi.org/10.3390/antibiotics14040398 - 12 Apr 2025
Abstract
Background: Enterococcus species present significant health risks due to their widespread presence in humans, animals, and the environment. This study examined the patterns of antimicrobial resistance (AMR) and the presence of carbapenemase-producing Enterococcus species from various sources. Methods: Between November 2023
[...] Read more.
Background: Enterococcus species present significant health risks due to their widespread presence in humans, animals, and the environment. This study examined the patterns of antimicrobial resistance (AMR) and the presence of carbapenemase-producing Enterococcus species from various sources. Methods: Between November 2023 and February 2024, 500 samples were collected in Lagos State, including 350 clinical human samples, 50 environmental samples, and 100 animal samples. The samples were processed, and Enterococcus isolates were identified and subjected to antimicrobial susceptibility tests (AST) by standard methods. Furthermore, carbapenemase (blaKPC and oxa-48) and virulence genes (gelE) were detected by real-time polymerase chain reaction (RT-PCR) methods using specific primers. Results: The overall prevalence of Enterococcus isolates was 4.6% (23/500), including 18 E. faecalis and 5 E. faecium. The source prevalence was 24% (12/50) from the environmental samples, 5% (5/100) from animal sources, and 1.7% (6/350) from the clinical samples. All Enterococcus isolates were 100% resistant to ciprofloxacin, erythromycin, imipenem, vancomycin, and ampicillin. However, 91% were susceptible to gentamicin. Six (6) distinct resistance profiles were observed, with the pattern AMP-ERY-TGC-CIP-TS-VA-CHL-AUG-MEM-IMI being the most frequent in 12 E. faecalis (4 isolates from humans, 2 from animals, and 6 from the environment). Notably, 39.1% (9/23) of multiple-drug resistant Enterococcus isolates harbored the gelE virulence gene, including seven E. faecalis (five environmental and two human) and two E. faecium from animal sources. The E. faecalis strains HB003 and HB050, from human bacteremia cases carrying gelE, were the first in Nigeria to produce blaKPC and oxa-48 carbapenemase genes. Conclusions: This study revealed the emergence of carbapenemase-producing Enterococcus species in our environment. A one-health approach and further molecular studies are essential to mitigate the spread and understand the transmission dynamics.
Full article
(This article belongs to the Special Issue Livestock Antibiotic Use and Resistance)
►▼
Show Figures

Figure 1

Journal Menu
► ▼ Journal Menu-
- Antibiotics Home
- Aims & Scope
- Editorial Board
- Reviewer Board
- Topical Advisory Panel
- Instructions for Authors
- Special Issues
- Topics
- Sections & Collections
- Article Processing Charge
- Indexing & Archiving
- Editor’s Choice Articles
- Most Cited & Viewed
- Journal Statistics
- Journal History
- Journal Awards
- Society Collaborations
- Conferences
- Editorial Office
Journal Browser
► ▼ Journal BrowserHighly Accessed Articles
Latest Books
E-Mail Alert
News
Topics
Topic in
Antibiotics, Biomedicines, JCM, Pharmaceuticals, Pharmaceutics
Challenges and Future Prospects of Antibacterial Therapy
Topic Editors: Kwang-sun Kim, Zehra EdisDeadline: 30 June 2025
Topic in
Antibiotics, Antioxidants, JoF, Microbiology Research, Microorganisms
Redox in Microorganisms, 2nd Edition
Topic Editors: Michal Letek, Volker BehrendsDeadline: 31 July 2025
Topic in
Agriculture, Animals, Veterinary Sciences, Antibiotics, Zoonotic Diseases
Animal Diseases in Agricultural Production Systems: Their Veterinary, Zoonotic, and One Health Importance, 2nd Edition
Topic Editors: Ewa Tomaszewska, Beata Łebkowska-Wieruszewska, Tomasz Szponder, Joanna Wessely-SzponderDeadline: 30 September 2025
Topic in
Antibiotics, JPM, Pharmaceuticals, Pharmaceutics, Medicines
Pharmacokinetic and Pharmacodynamic Modelling in Drug Discovery and Development
Topic Editors: Inaki F. Troconiz, Victor Mangas Sanjuán, Maria Garcia-Cremades MiraDeadline: 31 October 2025

Conferences
26–29 August 2025
The 5th International Symposium on Frontiers in Molecular Science
Molecular Regulatory Mechanisms of Biological Function and Drug Discovery based on Protein Structure/Function Analysis
Molecular Regulatory Mechanisms of Biological Function and Drug Discovery based on Protein Structure/Function Analysis

21–23 May 2025
The 4th International Electronic Conference on Antibiotics: Challenges and Strategies for the Antibiotic Resistance Crisis

Special Issues
Special Issue in
Antibiotics
Antimicrobial Resistance and Zoonoses, 2nd Edition
Guest Editors: Marina Spînu, Magdalena RzewuskaDeadline: 20 April 2025
Special Issue in
Antibiotics
The Use of Antibiotics in Aquaculture: Antimicrobial Resistance, Efficacy and Safety, Ethical and Environmental Concerns
Guest Editor: Øivind BerghDeadline: 20 April 2025
Special Issue in
Antibiotics
Resistance and Evolving Biology in Mycobacteria: Multidisciplinarity as a Contemporary Approach
Guest Editors: Irena Arandjelovic, Dragana VukovicDeadline: 30 April 2025
Special Issue in
Antibiotics
Antimicrobial Resistance in Animals and Animal Products and Its Environmental Transmission Aspects
Guest Editors: Nikolaos Solomakos, Thomai Lazou, Andreana PexaraDeadline: 30 April 2025
Topical Collections
Topical Collection in
Antibiotics
Antibiotics in Ophthalmology Practice
Collection Editor: Sanjay Marasini
Topical Collection in
Antibiotics
Staphylococcus— Molecular Pathogenesis, Virulence Regulation and Antibiotics Resistance
Collection Editor: Ewa Szczuka
Topical Collection in
Antibiotics
Editorial Board Members' Collection Series: Structural Aspects of AMPs and Antimicrobials
Collection Editors: J. Michael Conlon, Marc Maresca, Bong-Jin Lee, Aurélie Tasiemski
Topical Collection in
Antibiotics
Synthetic and Natural Products-Based Antimicrobial and Antiparasitic Agents
Collection Editor: Antonio Eduardo Miller Crotti